Part 1: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 1: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 1: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

Laboratory abnormalities as characterized by type, frequency, severity.

Accessed from baseline up to 90 days after the last dose of study treatment.

Part 1: Percent of participants with Best Overall Response (BOR)

BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

Assessed for approximately 2 years

Part 1: Percentage of Participants with an Objective Response Rate (ORR)

ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

Assessed from enrollment for approximately 2 years.

Part 1: Percentage of participants with a complete response rate (CRR)

Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

Assessed for approximately 2 years

Part 1: Time to Response (TTR)

TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

Assessed for approximately 2 years.

Part 1: Duration of Response (DOR)

DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 1: Duration of Complete Response (DOCR)

DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 1: Time of Progression Free Survival (PFS)

Progression free survival (IMWG response criteria)

Assessed from enrollment until Progressive Disease or death for approximately 2 years.

Part 1: Time of Overall Survival (OS)

OS is the duration of time from first dose of study treatment to death.

Assessed for approximately 2 years

Part 1: Minimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is the proportion of participants acheiving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

Assessed for approximately 2 years

Part 1: Concentrations of carfilzomib

Pre-dose and post-dose concentrations of cafilzomib

Once approximately 7 weeks from enrollment.

Part 1: Concentrations of elranatamab

Pre-dose and post-dose concentrations of elranatamab

Assessed for approximately 2 years.

Part 1: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

Percent of participants with positive ADA to elranatamab when given in combination with carfilzomib and dexamethasone

Assessed for approximately 2 years.

Part 2A: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 2A: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 2A: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

Laboratory abnormalities as characterized by type, frequency, severity.

Accessed from baseline up to 90 days after the last dose of study treatment.

Part 2A: Percent of participants with Best Overall Response (BOR)

BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

Assessed for approximately 2 years

Part 2A: Percentage of Participants with an Objective Response Rate (ORR)

ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

Assessed from enrollment for approximately 2 years.

Part 2A: Percentage of participants with a complete response rate (CRR)

Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

Assessed for approximately 2 years

Part 2A: Time to Response (TTR)

TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

Assessed for approximately 2 years.

Part 2A: Duration of Response (DOR)

DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 2A: Duration of Complete Response (DOCR)

DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 2A: Time of Progression Free Survival (PFS)

Progression free survival (IMWG response criteria)

Assessed from enrollment until Progressive Disease or death for approximately 2 years.

Part 2A: Time of Overall Survival (OS)

OS is the duration of time from first dose of study treatment to death.

Assessed for approximately 2 years

Part 2A: Minimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

Assessed for approximately 2 years

Part 2A: Concentrations of maplirpacept

Pre-dose and post-dose concentrations of maplirpacept

Assessed for approximately 2 years.

Part 2A: Concentrations of elranatamab

Pre-dose and post-dose concentrations of elranatamab

Assessed for approximately 2 years.

Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

Assessed for approximately 2 years.

Part 2A: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

Assessed for approximately 2 years.

Part 2B: Number of Participants with Treatment Emergent Adverse Events (TEAE) by Seriousness and Relationship to Treatment

Counts of participants who had TEAEs, defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator. Participants with multiple occurrences of an AE within a category were counted once within the category.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 2B: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity.

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Assessed from baseline up to 90 days after last dose of study treatment.

Part 2B: Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities

Laboratory abnormalities as characterized by type, frequency, severity.

Accessed from baseline up to 90 days after the last dose of study treatment.

Part 2B: Percent of participants with Best Overall Response (BOR)

BOR is defined as the best response recorded from treatment start until disease progression/recurrence based on International Myeloma Working Group (IMWG) response criteria.

Assessed for approximately 2 years

Part 2B: Percentage of Participants with an Objective Response Rate (ORR)

ORR rate is defined as the percent of participants having a Best Overall Response (BOR) of confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) according to IMWG.

Assessed from enrollment for approximately 2 years.

Part 2B: Percentage of participants with a complete response rate (CRR)

Complete Response/ stringent Complete Response (CR+sCR) rate per IMWG response criteria as determined by investigator.

Assessed for approximately 2 years

Part 2B: Time to Response (TTR)

TTR is defined, for participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed.

Assessed for approximately 2 years.

Part 2B: Duration of Response (DOR)

DOR is defined, for participants with an objective response per IMWG criteria, as the time from the first documentation of objective response that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 2B: Duration of Complete Response (DOCR)

DOCR is defined, for participants with a Complete Response/stringent Complete Response (CR+sCR) per IMWG criteria, as the time from the first documentation of CR/sCR that is subsequently confirmed, until the first documentation of confirmed progressive disease (PD) per IMWG criteria.

Assessed for approximately 2 years.

Part 2B: Time of Progression Free Survival (PFS)

Progression free survival (IMWG response criteria)

Assessed from enrollment until Progressive Disease or death for approximately 2 years.

Part 2B: Time of Overall Survival (OS)

OS is the duration of time from first dose of study treatment to death.

Assessed for approximately 2 years

Part 2B: Minimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is the proportion of participants achieving CR+sCR with negative MRD, per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death or start of new anticancer therapy.

Assessed for approximately 2 years

Part 2B: Concentrations of maplirpacept

Pre-dose and post-dose concentrations of maplirpacept

Assessed for approximately 2 years.

Part 2B: Concentrations of elranatamab

Pre-dose and post-dose concentrations of elranatamab

Assessed for approximately 2 years.

Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

Percent of participants with positive ADA to elranatamab when given in combination with maplirpacept

Assessed for approximately 2 years.

Part 2B: Percentage of participants with positive anti-drug antibodies (ADA) against maplirpacept

Percent of participants with positive ADA to elranatamab when given in combination with elranatamab

Assessed for approximately 2 years.